肿瘤坏死因子抑制剂药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023年全球肿瘤坏死因子（TNF）抑制剂药物市值为413亿美元，预计2024-2032年复合年增长率为2.2%。该市场的成长很大程度上归因于牛皮癣、类风湿性关节炎和发炎性肠道疾病等自体免疫疾病发生率的增加。随着对这些疾病的认识和诊断能力的提高，对有效治疗方案的需求显着增加。 TNF 抑制剂因其在控制慢性发炎性疾病症状方面的功效而闻名，已成为治疗方案的关键组成部分。

整个肿瘤坏死因子抑制剂药物产业根据药物类别、适应症、给药途径、配销通路和地区进行分类。

肿瘤坏死因子抑制剂药物市场依药物类别分为聚乙二醇赛妥珠单抗、阿达木单抗、英夫利西单抗、依那西普和戈利木单抗。 2023年，阿达木单抗领域领先市场，估值达242亿美元。阿达木单抗是一种专注于肿瘤坏死因子（TNF）的单株抗体，由于其广泛的疗效、值得称讚的安全性以及在各种自体免疫疾病中的广泛使用，在TNF 抑制剂药物领域拥有巨大的市场占有率。新颖配方和给药方法的不断开发增强了其市场地位。

依适应症细分，肿瘤坏死因子抑制剂药物市场包括化脓性汗腺炎、类风湿性关节炎、干癣性干癣性关节炎、干癣、克隆氏症、僵直性脊椎炎、溃疡性结肠炎、幼年特发性关节炎等。 2023年，类风湿性关节炎细分市场以42.0%的份额引领市场。类风湿性关节炎（RA）是一种主要影响关节的慢性发炎性疾病，导致疼痛、肿胀和潜在的关节损伤，导致大量患者寻求有效的治疗。 RA 盛行率的上升，加上认知度和诊断率的提高，刺激了 RA 治疗中对 TNF 抑制剂的需求。

2023年，北美引领全球肿瘤坏死因子抑制剂药物市场，营收达到170亿美元，预计到2032年可能达到200亿美元。它们处于开发创新TNF 抑制剂的前沿。北美强大的医疗保健系统与既定的监管途径相结合，确保了新疗法的快速进入和接受。患者意识的提高和获得尖端治疗方案的机会巩固了北美在全球 TNF 抑制剂药物市场的主导地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 自体免疫疾病盛行率增加
    • 扩大治疗适应症
    • 生物技术和药物开发的进步
  • 产业陷阱与挑战
    • 治疗费用高
    • 副作用和安全问题
• 成长潜力分析
• 监管环境
• 管道分析
• 专利分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 阿达木单抗
  • 品牌化
  • 生物相似药
• 依那西普
  • 品牌化
  • 生物相似药
• 英夫利西单抗
  • 品牌化
  • 生物相似药
• 戈利木单抗
• 聚乙二醇赛妥珠单抗

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 类风湿关节炎
• 牛皮癣
• 银屑病关节炎
• 克罗恩病
• 溃疡性结肠炎
• 僵直性脊椎炎
• 幼年特发性关节炎
• 化脓性汗腺炎
• 其他适应症

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 皮下注射
• 静脉注射

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bio-Thera Solutions, Ltd.
• Janssen Biotech, Inc.
• Merck and Co., Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Group AG
• UCB, Inc.

The Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market was valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from 2024-2032. The market's growth is largely attributed to the increasing incidence of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. As awareness and diagnostic capabilities for these conditions improve, the demand for effective treatment options has risen significantly. TNF inhibitors, known for their efficacy in controlling symptoms of chronic inflammatory diseases, have become a key component in treatment protocols.

The overall tumor necrosis factor inhibitor drugs industry is classified based on the drug class, indication, route of administration, distribution channel, and region.

The tumor necrosis factor inhibitor drugs market is categorized by drug class into certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. In 2023, the adalimumab segment led the market, commanding a valuation of USD 24.2 billion. Adalimumab, a monoclonal antibody with a focus on tumor necrosis factor (TNF), boasts a significant market share in the TNF inhibitor drugs arena, thanks to its broad efficacy, commendable safety profile, and prevalent use across various autoimmune diseases. The continuous development of novel formulations and delivery methods bolsters its market presence.

Segmented by indication, the tumor necrosis factor inhibitor drugs market includes hidradenitis suppurativa, rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, juvenile idiopathic arthritis, and other conditions. In 2023, the rheumatoid arthritis segment led the market with a 42.0% share. Rheumatoid arthritis (RA) is a chronic inflammatory disorder primarily impacting joints, leading to pain, swelling, and potential joint damage, resulting in a significant patient population seeking effective treatment. The rising prevalence of RA, combined with heightened awareness and diagnostic rates, has spurred the demand for TNF inhibitors in RA treatment.

In 2023, North America led the global tumor necrosis factor inhibitor drugs market with revenues reaching USD 17 billion, and projections suggest it could hit USD 20 billion by 2032. The region's leadership is largely due to the presence of top-tier pharmaceutical and biopharmaceutical companies, which are at the forefront of developing innovative TNF inhibitors. North America's strong healthcare system, paired with established regulatory pathways, ensures swift market entry and acceptance of new therapies. Heightened patient awareness and access to cutting-edge treatment options solidify North America's dominant stance in the global TNF inhibitor drugs market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of autoimmune diseases
    • 3.2.1.2 Expansion of therapeutic indications
    • 3.2.1.3 Advancements in biotechnology and drug development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Patent analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Adalimumab
  • 5.2.1 Branded
  • 5.2.2 Biosimilar
• 5.3 Etanercept
  • 5.3.1 Branded
  • 5.3.2 Biosimilar
• 5.4 Infliximab
  • 5.4.1 Branded
  • 5.4.2 Biosimilar
• 5.5 Golimumab
• 5.6 Certolizumab pegol

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Rheumatoid arthritis
• 6.3 Psoriasis
• 6.4 Psoriatic arthritis
• 6.5 Crohn's disease
• 6.6 Ulcerative colitis
• 6.7 Ankylosing spondylitis
• 6.8 Juvenile idiopathic arthritis
• 6.9 Hidradenitis suppurativa
• 6.10 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous injection
• 7.3 Intravenous injection

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
• 10.4 Bio-Thera Solutions, Ltd.
• 10.5 Janssen Biotech, Inc.
• 10.6 Merck and Co., Inc.
• 10.7 Pfizer Inc.
• 10.8 Samsung Bioepis Co., Ltd.
• 10.9 Sandoz Group AG
• 10.10 UCB, Inc.